Abstract:80 Objectives: APOE4 is identified to be a high risk factor for late-onset Alzheimer Disease. Our objective is to study the APOE4 effects on brain tau deposition and glucose metabolism in mild cognition impairment (MCI) patients using quantitative [18F]AV1451 and [18F]FDG PET. Methods: [18F]AV1451 tau PET scans for 63 (24 subjects of APOE4) MCI patients and longitudinal [18F]FDG PET scans over a 96-month period in 48 (24 subjects of APOE4) MCI patients , as well as MRIs, and demographic information, were downloaded from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The downloaded preprocessed PET images were aligned, averaged, reoriented and then interpolated into a standard image and voxel size (image volume 160×160×96, 1.5x1.5x1.5 mm in x, y, z), and smoothed to a uniform resolution of 8 mm in full width at half maximum (FWHM). The structural MRIs were used for PET spatial normalization and region of interest (ROI) definition in standard space. An iterative reblurred Van Cittertiteration method was used for partial volume correction (PVC) on the all PET images [1], where a 3-D Gaussian kernel of 8 mm FWHM was used for spatial smoothing function h, step length α=1.5, and the iteration was stopped if relative percent change of PVC images < 1%. Regions of interest (ROIs) including cerebellum gray matter for reference tissue were manually drawn on the MRI template using PMOD software (PMOD Technologies Ltd., Zurich, Switzerland) in standard MNI space. Standard uptake value ratio (SUVR) images relative to the cerebellum ROI were calculated in the MNI space. ROI SUVRs were obtained by applying ROIs to SUVR images. A statistical software SAS was used for all statistical analysis. A general linear model was used to evaluate APOE4 effects on ROI SUVRs with adjustments of gender, age, and education level. For evaluation of PVC effects on our results, all ROI SUVRs from non-partial volume corrected (nonPVC) PET images were also analyzed. Results: Based PVC PET images, the parietal, medial temporal, lateral temporal, amygdala, hippocampus, caudate, thalamus, and post-cingulate regions had greater longitudinal decreases in [18F]FDG uptake in the APOE4 carriers compared to non-carriers in patients with MCI (p<0.03). In [18F]AV1451 tau PET study, the medial temporal, anterior cingulate, Amygdala, fusiform, parahipocampus, putamen, and ventral Striatum showed significant higher SUVR in the APOE4 carriers compared to non-APOE4 carriers (p<0.02). The statistical levels were reduced in non-PVC based ROI SUVR comparison. Specifically, in [18F]FDG PET study, we observe a near but not significant APOE4-mediated effect in FDG uptake in the amgydala, posterior cingulate, and the hippocampus (p= 0.14, 0.10, and 0.07 for amgydala, posterior cingulate, and the hippocampus, respectively) without PVC . The p value was reduced to 0.053 for ventral striatum in nonPVC [18F]AV1451 tau PET study. Conclusions: The study identified APOE4 correlates with brain regions that were associated with decline in glucose uptake over time and increased tau deposition. Partial volume correction is suggested for AD study with quantitative [18F]AV1451 or longitudinal [18F]FDG PET . Reference [1] Jussi Tohkaa, Anthonin Reilhac. NeuroImage. 2008; 39:1570-1584.

Using Positron Emission Tomography And Florbetapir F 18 To Image Cortical Amyloid In Patients With Mild Cognitive Impairment Or Dementia Due To Alzheimer Disease

P1‐375: APOE ∊4 Effects on Florbetapir F18 PET in Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging

Closer Correlations Between Florbetapir PET Measurements of Amyloid Plaque Burden Using a Cerebral White Matter Reference Region and Alzheimer’s Disease‐related Hypometabolism

Apolipoprotein E Ε4 and Age Effects on Florbetapir Positron Emission Tomography in Healthy Aging and Alzheimer Disease

Florbetapir PET Measurements of Amyloid Plaque Deposition Are More Closely Correlated with Cross‐Sectional and Longitudinal Cognitive and Clinical Measurements Using a White Matter Reference Region of Interest

RELATIONSHIPS BETWEEN MEAN CORTICAL AMYLOID BURDEN AND REGIONAL GRAY MATTER REDUCTIONS IN ALZHEIMER’S DEMENTIA, MILD COGNITIVE IMPAIRMENT AND UNIMPAIRED OLDER ADULTS

P1‐118: QUANTIFICATION OF AMYLOID BURDEN FROM FLORBETAPIR PET WITHOUT USING TARGET AND REFERENCE REGIONS: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH

O3‐04‐02: FLORTAUCIPIR PAIRED HELICAL FILAMENT TAU BURDEN AND CORRELATION WITH COGNITIVE DECLINE IN MCI PATIENTS WITHOUT ANY Aβ

Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads

QUANTIFICATION OF AMYLOID BURDEN FROM FLORBETAPIR PET IMAGES WITHOUT USING TARGET AND REFERENCE REGIONS: PRELIMINARY FINDINGS BASED ON THE DEEP LEARNING 3D CONVOLUTIONAL NEURAL NETWORK APPROACH

IC‐P‐010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOID‐β BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED

Quantitative Imaging Apoe4 Effects On Brain Tau Deposition And Glucose Metabolism In Mild Cognitive Impairment Patients With [F-18]Av1451 And [F-18]Fdg Pet

P2‐071: comparing cerebral white matter, cerebellar, and pontine reference regions to characterize florbetapir pet measurements of amyloid‐β burden in psen1 e280a mutation carriers and noncarriers from the colombian autosomal dominant alzheimer's disease kindred

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

P1‐408: 18F‐FDG AND 18F‐AV45 POSITRON EMISSION TOMOGRAPHY IN ALZHEIMER'S DISEASE

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment

Florbetapir PET Analysis of Amyloid-Β Deposition in the Presenilin 1 E280A Autosomal Dominant Alzheimer's Disease Kindred: a Cross-Sectional Study

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

Application of 18F-AV45 PET Imaging in Subtle Cognitive Decline and Mild Cognitive Impairment Patients

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer's disease

The Image Quality, Amyloid-Β Detectability, and Acquisition Time of Clinical Florbetapir Positron Emission Tomography in Alzheimer's Disease and Healthy Adults.